Jean Koff MD, MSc

Department of Hematology and Medical Oncology
Associate Professor

(404) 778-3942
jkoff@emory.edu

Overview

Dr. Koff is a clinical investigator in the Bone Marrow and Stem Cell Transplant Center with a disease focus in lymphoma.

Dr. Koff received her MD and graduated magna cum laude from Emory University School of Medicine in Atlanta, Georgia. Her postgraduate medical education included a J. Willis Hurst Residency in Internal Medicine at Emory University and a Fellowship in Hematology and Medical Oncology at Winship Cancer Institute, where she was Chief Fellow in her final year.

She holds memberships with American Medical Association, American Society of Clinical Oncology and American Society of Hematology.

Academic Appointment

Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Education

Degrees

MD from Emory University School of Medicine

Research

Publications

Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
Clin Lymphoma Myeloma Leuk Volume: 25 Page(s): e183 - e199.e8
04/01/2025 Authors: Nastoupil LJ; Andersen CR; Ayers A; Wang Y; Habermann TM; Chihara D; Kahl BS; Link BK; Koff JL; Cohen JB
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.
Am J Hematol Volume: 100 Page(s): 606 - 615
04/01/2025 Authors: Yamshon S; Koff JL; Larson MC; Kahl BS; Casulo C; Lossos IS; Haddadi S; Stanchina M; Chihara D; Ayers A
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium.
Blood Adv Volume: 9 Page(s): 1013 - 1023
03/11/2025 Authors: Day JR; Larson MC; Durani U; Koff JL; Wang Y; Habermann TM; Lossos IS; Nastoupil LJ; Strouse C; Chihara D
Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.
Blood Cancer Discov Volume: 6 Page(s): 79 - 93
03/04/2025 Authors: Flowers CR; Anantha RW; Leautaud V; Desai P; Donald CE; Hildebrandt MAT; Koff JL; Tamimi RM; Cozen W; Nze C
Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell Lymphoma.
Clin Lymphoma Myeloma Leuk
02/20/2025 Authors: Zeng F; Zhang H; Wang S; Passang T; Li Y; Funk CR; Wyman S; O'Leary CB; Abousaud AI; Liu Y
Human immune organoids to decode B cell response in healthy donors and patients with lymphoma.
Nat Mater Volume: 24 Page(s): 297 - 311
02/01/2025 Authors: Zhong Z; Quiones-Prez M; Dai Z; Juarez VM; Bhatia E; Carlson CR; Shah SB; Patel A; Fang Z; Hu T
T Cells Spatially Regulate B Cell Receptor Signaling in Lymphomas through H3K9me3 Modifications.
Adv Healthc Mater Volume: 14 Page(s): e2401192
02/01/2025 Authors: Britto LS; Balasubramani D; Desai S; Phillips P; Trehan N; Cesarman E; Koff JL; Singh A
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature.
Blood Adv Volume: 8 Page(s): 5939 - 5948
12/10/2024 Authors: Bommier C; Link BK; Gysbers BJ; Maurer MJ; Larson MC; Khurana A; Wang Y; Thompson CA; Chihara D; Alderuccio JP
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
Haematologica Volume: 109 Page(s): 2177 - 2185
07/01/2024 Authors: Maurer MJ; Casulo C; Larson MC; Habermann TM; Lossos IS; Wang Y; Nastoupil LJ; Strouse C; Chihara D; Martin P
Engineering Improved CAR T Cell Products with A Multi-Cytokine Particle Platform for Hematologic and Solid Tumors.
Adv Healthc Mater Volume: 13 Page(s): e2302425
06/01/2024 Authors: Lin HK; Uricoli B; Freeman R; Hossian AN; He Z; Anderson JYL; Neffling M; Legier JM; Blake DA; Doxie DB
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
Am J Hematol Volume: 99 Page(s): 408 - 421
03/01/2024 Authors: Cerhan JR; Maurer MJ; Link BK; Feldman AL; Habermann TM; Jaye DL; Burack WR; McDonnell TJ; Vega F; Chapman JR
Important Considerations in the Diagnosis and Management of Post-transplant Lymphoproliferative Disorder.
Curr Oncol Rep Volume: 25 Page(s): 883 - 895
08/01/2023 Authors: Lee M; Abousaud A; Harkins RA; Marin E; Balasubramani D; Churnetski MC; Peker D; Singh A; Koff JL
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies.
Blood Adv Volume: 7 Page(s): 2459 - 2462
06/13/2023 Authors: Chang A; Koff JL; Lai L; Orellana-Noia VM; Surati M; Leal AMK; Ellis ML; Wali B; Moreno A; Linderman SL
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
Hematol Oncol Volume: 41 Suppl 2 Page(s): 597 - 598
06/01/2023 Authors: Bond DA; Wei L; Yildiz V; Reneau J; Sawalha Y; Christian B; Brammer J; Epperla N; Koff J; Dendorfer A
Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.
Blood Volume: 141 Page(s): 1888 - 1893
04/13/2023 Authors: Alderuccio JP; Reis IM; Koff JL; Larson MC; Chihara D; Zhao W; Haddadi S; Habermann TM; Martin P; Chapman JR
Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas.
Nat Mater Volume: 22 Page(s): 511 - 523
04/01/2023 Authors: Shah SB; Carlson CR; Lai K; Zhong Z; Marsico G; Lee KM; Flix Vlez NE; Abeles EB; Allam M; Hu T
Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms.
Commun Biol Volume: 6 Page(s): 295
03/20/2023 Authors: Taghi Khani A; Kumar A; Sanchez Ortiz A; Radecki KC; Aramburo S; Lee SJ; Hu Z; Damirchi B; Lorenson MY; Wu X
Post-transplant lymphoproliferative disorder risk and outcomes in renal transplant patients treated with belatacept immunosuppression.
Front Transplant Volume: 2 Page(s): 1280993
01/01/2023 Authors: Koff JL; Karadkhele GM; Switchenko JM; Rupji M; Little K; Larsen CP
Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
Cancer Res Commun Volume: 2 Page(s): 1684 - 1692
12/01/2022 Authors: Chang A; Akhtar A; Lai L; Orellana-Noia VM; Linderman SL; McCook-Veal AA; Switchenko JM; Saini M; Valanparambil RM; Blum KA
CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S281 - S282
10/01/2022 Authors: Chang A; Lai L; Akhtar A; Linderman S; Orellana-Noia V; Saini M; Valanparambil R; Blum K; Allen P; Lechowicz M
Herpes simplex virus lymphadenitis is associated with tumor reduction in a patient with chronic lymphocytic leukemia.
J Clin Invest Volume: 132
09/15/2022 Authors: Chang A; Sholukh AM; Wieland A; Jaye DL; Carrington M; Huang M-L; Xie H; Jerome KR; Roychoudhury P; Greninger AL
Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
J Clin Oncol Volume: 40 Page(s): 3020 - 3031
09/10/2022 Authors: Chang A; Akhtar A; Linderman SL; Lai L; Orellana-Noia VM; Valanparambil R; Ahmed H; Zarnitsyna VI; McCook-Veal AA; Switchenko JM
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey.
Blood Adv Volume: 6 Page(s): 2745 - 2756
05/10/2022 Authors: Harkins RA; Patel SP; Lee MJ; Switchenko JM; Ansell SM; Bartlett NL; Blum KA; Cashen AF; Casulo C; Friedberg JW
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
Lancet Haematol Volume: 9 Page(s): e289 - e300
04/01/2022 Authors: Casulo C; Larson MC; Lunde JJ; Habermann TM; Lossos IS; Wang Y; Nastoupil LJ; Strouse C; Chihara D; Martin P
PI3K/ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
Blood Volume: 139 Page(s): 523 - 537
01/27/2022 Authors: Funk CR; Wang S; Chen KZ; Waller A; Sharma A; Edgar CL; Gupta VA; Chandrakasan S; Zoine JT; Fedanov A
Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma.
Blood Cancer J Volume: 11 Page(s): 2
01/07/2021 Authors: Merdan S; Subramanian K; Ayer T; Van Weyenbergh J; Chang A; Koff JL; Flowers C
Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study
Volume: 136
11/05/2020 Authors: Lee HJ; Choi MY; Siddiqi T; Wierda WG; Barrientos JC; Lamanna N; Goldenberg A; Isufi I; Tuscano J; Subbiah S
Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era
Volume: 136
11/05/2020 Authors: Santapuram PR; Rupji M; Graiser M; Waller EK; Blum KA; Allen PB; Koff JL; Heffner L; Lechowicz MJ; Lonial S
Linking Environmental Exposures to Molecular Pathogenesis in Non-Hodgkin Lymphoma Subtypes.
Cancer Epidemiol Biomarkers Prev Volume: 29 Page(s): 1844 - 1855
10/01/2020 Authors: Moubadder L; McCullough LE; Flowers CR; Koff JL
Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.
Cancer Volume: 126 Page(s): 3493 - 3503
08/01/2020 Authors: Lee MJ; Koff JL; Switchenko JM; Jhaney CI; Harkins RA; Patel SP; Dave SS; Flowers CR
Machine learning prediction of survival in diffuse large B-cell lymphoma based on gene-expression profiling.
Volume: 38
05/20/2020 Authors: Merdan S; Subramanian K; Ayer T; Koff JL; Chang A; Van Weyenbergh J; Flowers C
Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma.
Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 234 - 243.e10
04/01/2020 Authors: Patel SP; Harkins RA; Lee MJ; Flowers CR; Koff JL
Insurance status impacts overall survival in Burkitt lymphoma.
Volume: 60 Page(s): 3225 - 3234
12/01/2019 Authors: Goldstein JS; Switchenko JM; Behera M; Flowers CR; Koff JL
Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma.
Blood Volume: 134 Page(s): 19
11/13/2019 Authors: Li X; Kositsky R; Reddy A; Love C; Naresh K; Koff JL; Nystrand I; Lepp S; Pasanen A; Karjalainen-Lindsberg M-L
Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma.
Expert Rev Hematol Volume: 12 Page(s): 959 - 973
11/01/2019 Authors: Harkins RA; Chang A; Patel SP; Lee MJ; Goldstein JS; Merdan S; Flowers CR; Koff JL
Characterizing Lymphoma Incidence and Disparities for a Cancer Center Catchment Region.
Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): 699 - 708.e5
11/01/2019 Authors: Ayers AA; Lyu L; Dance K; Ward KC; Flowers CR; Koff JL; McCullough LE
Examining genetic ancestry in diffuse large B-cell lymphoma (DLBCL)
Volume: 79
07/01/2019 Authors: Lee MJ; Jhaney CI; Flowers CR; Koff JL
Racial and Socioeconomic Disparities in Mantle Cell Lymphoma.
Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): e312 - e320
06/01/2019 Authors: Shah NN; Xi Y; Liu Y; Koff JL; Flowers CR; Behera M; Cohen JB
Influenza Vaccination Documentation Rates During the First Year After Diagnosis of Diffuse Large B Cell Lymphoma.
Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): 239 - 243
04/01/2019 Authors: Chang A; Payne JB; Allen PB; Koff JL; Ahmed R; Flowers CR; Bednarczyk RA
Improving cancer-specific outcomes in solid organ transplant recipients: Where to begin?
Cancer Volume: 125 Page(s): 838 - 842
03/15/2019 Authors: Koff JL; Waller EK
History of autoimmune conditions and lymphoma prognosis.
Blood Cancer J Volume: 8 Page(s): 73
08/01/2018 Authors: Kleinstern G; Maurer MJ; Liebow M; Habermann TM; Koff JL; Allmer C; Witzig TE; Nowakowski GS; Micallef IN; Johnston PB
Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.
Leuk Lymphoma Volume: 59 Page(s): 1700 - 1709
07/01/2018 Authors: Chen Q; Staton AD; Ayer T; Goldstein DA; Koff JL; Flowers CR
Impact of the posttransplant lymphoproliferative disorder subtype on survival.
Cancer Volume: 124 Page(s): 2327 - 2336
06/01/2018 Authors: Koff JL; Li J-X; Zhang X; Switchenko JM; Flowers CR; Waller EK
Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
Expert Opin Investig Drugs Volume: 27 Page(s): 513 - 522
06/01/2018 Authors: Valla K; Flowers CR; Koff JL
Impact of individual comorbidities on post-transplant outcomes for elderly patients with non-Hodgkin lymphoma (NHL).
Volume: 36
05/20/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff JL; Gupta VA; Lechowicz MJ; Nooka AK; Kaufman JL; Lonial S; Waller EK
Racial and socioeconomic disparities in mantle cell lymphoma.
Volume: 36
05/20/2018 Authors: Shah N; Liu Y; Xi Y; Flowers C; Koff JL; Behera M; Cohen JB
Outcomes in non-Hodgkin lymphoma by Latino country-of-origin (COO).
Volume: 36
05/20/2018 Authors: Calzada O; Xi Y; Behera M; Koff JL; Flowers C; Liu Y; Cohen JB
Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant Volume: 24 Page(s): 973 - 982
05/01/2018 Authors: Hosoba S; Waller EK; Shenvi N; Graiser M; Easley KA; Al-Kadhimi Z; Andoh A; Antun AG; Barclay S; Josephson CD
Effective management strategies for patients with marginal zone lymphoma.
Future Oncol Volume: 14 Page(s): 1213 - 1222
05/01/2018 Authors: Rosand CB; Valla K; Flowers CR; Koff JL
Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.
Leuk Lymphoma Volume: 59 Page(s): 888 - 895
04/01/2018 Authors: Guidot DM; Switchenko JM; Nastoupil LJ; Koff JL; Blum KA; Maly J; Flowers CR; Cohen JB
Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort.
Volume: 18 Page(s): e115 - e121
02/01/2018 Authors: Koff JL; Rai A; Flowers CR
Genetic and Functional Drivers of Diffuse Large BCell Lymphoma.
Cell Volume: 171 Page(s): 481 - 494.e15
10/05/2017 Authors: Reddy A; Zhang J; Davis NS; Moffitt AB; Love CL; Waldrop A; Leppa S; Pasanen A; Meriranta L; Karjalainen-Lindsberg M-L
Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?
Cancer Volume: 123 Page(s): 3222 - 3225
09/01/2017 Authors: Koff JL; Flowers CR
Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.
Oncogene Volume: 36 Page(s): 4224 - 4232
07/20/2017 Authors: Guo X; Koff JL; Moffitt AB; Cinar M; Ramachandiran S; Chen Z; Switchenko JM; Mosunjac M; Neill SG; Mann KP
Dose dependent association of early red blood cell transfusion with increased risk of graft versus host disease and worse survival after allogeneic hematopoietic stem cell transplantation
Volume: 52 Page(s): S207 - S208
07/01/2017 Authors: Waller EK; Hosoba S; Al-Kadhimi Z; Andoh A; Antun AG; Barclay S; Easley KA; Josephson CD; Khoury HJ; Koff JL
THE COST-EFFECTIVENESS OF PRECISION MEDICINE TREATMENT STRATEGIES FOR DIFFUSE LARGE B-CELL LYMPHOMA
Volume: 20 Page(s): A107 - A107
05/01/2017 Authors: Chen Q; Staton AD; Ayer T; Goldstein DA; Koff JL; Flowers CR
CD30 Expression Is Not Acquired at Time of Relapse in Diffuse Large B-Cell Lymphoma
Volume: 128
12/02/2016 Authors: Calzada O; Bradley KT; Switchenko J; Staton AD; Koff JL; Flowers CR; Cohen JB
An Evaluation of the Role of Surveillance Imaging in Mantle Cell Lymphoma in First Remission
Volume: 128
12/02/2016 Authors: Guidot DM; Switchenko J; Nastoupil LJ; Koff JL; Flowers C; Cohen JB
Assessing the Feasibility of Pathology Informatics Approaches for Subtyping Diffuse Large B-Cell Lymphoma (DLBCL)
Volume: 128
12/02/2016 Authors: Lewis SJ; Goldstein J; Farone M; Anh TP; Koff JL; Staton AD; Mobadersany P; Cooper L; Flowers C
Assessing the Feasibility of Pathology Informatics Approaches for Subtyping Diffuse Large B-Cell Lymphoma (DLBCL)
Volume: 128
12/02/2016 Authors: Lewis SJ; Goldstein J; Farone M; Anh TP; Koff JL; Staton AD; Mobadersany P; Cooper L; Flowers C
Relations Between Residential Proximity to EPA-Designated Toxic Release Sites and Diffuse Large B-Cell Lymphoma Incidence.
South Med J Volume: 109 Page(s): 606 - 614
10/01/2016 Authors: Bulka C; Nastoupil LJ; Koff JL; Bernal-Mizrachi L; Ward KC; Williams JN; Bayakly AR; Switchenko JM; Waller LA; Flowers CR
B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease.
Expert Rev Hematol Volume: 9 Page(s): 553 - 561
06/01/2016 Authors: Koff JL; Flowers CR
Resolving uncertainty in the spatial relationships between passive benzene exposure and risk of non-Hodgkin lymphoma.
Cancer Epidemiol Volume: 41 Page(s): 139 - 151
04/01/2016 Authors: Switchenko JM; Bulka C; Ward K; Koff JL; Bayakly AR; Ryan PB; Waller LA; Flowers CR
Integrating understanding of epidemiology and genomics in B-cell non-Hodgkin lymphoma as a pathway to novel management strategies.
Discov Med Volume: 21 Page(s): 181 - 188
03/01/2016 Authors: Glass S; Phan A; Williams JN; Flowers CR; Koff JL
Emerging treatments in Castleman disease - a critical appraisal of siltuximab.
Biologics Volume: 10 Page(s): 9 - 15
01/01/2016 Authors: Koff JL; Lonial S
Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma.
Leuk Lymphoma Volume: 57 Page(s): 842 - 851
01/01/2016 Authors: Chen Q; Ayer T; Nastoupil LJ; Koff JL; Staton AD; Chhatwal J; Flowers CR
Complex Karyotype in Mantle Cell Lymphoma (MCL) Is Associated with Inferior Progression-Free Survival in Patients (pts) Receiving R-Hypercvad Followed By Autologous Stem Cell Transplant
Volume: 126
12/03/2015 Authors: Lee MJ; Switchenko J; Thomas JS; Koff JL; Nastoupil L; Lechowicz MJ; Langston AA; Flowers C; Cohen JB
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
Volume: 171 Page(s): 539 - 546
11/01/2015 Authors: Cohen JB; Switchenko JM; Koff JL; Sinha R; Kaufman JL; Khoury HJ; Bumpers N; Colbert A; Hutchison-Rzepka A; Nastoupil LJ
Reply to Treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma.
Cancer Volume: 121 Page(s): 3748
10/15/2015 Authors: Williams JN; Koff JL; Flowers CR
To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes.
Curr Hematol Malig Rep Volume: 10 Page(s): 244 - 255
09/01/2015 Authors: Koff JL; Chihara D; Phan A; Nastoupil LJ; Williams JN; Flowers CR
Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.
Cancer Volume: 121 Page(s): 1800 - 1808
06/01/2015 Authors: Williams JN; Rai A; Lipscomb J; Koff JL; Nastoupil LJ; Flowers CR
New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy.
Expert Rev Anticancer Ther Volume: 15 Page(s): 531 - 544
05/01/2015 Authors: Chihara D; Nastoupil LJ; Williams JN; Lee P; Koff JL; Flowers CR
Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States.
Leuk Lymphoma Volume: 56 Page(s): 1295 - 1302
05/01/2015 Authors: Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Taylor M; Friedberg JW; Koff JL; Link BK; Cerhan JR; Dawson KL
Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma.
Leuk Lymphoma Volume: 56 Page(s): 383 - 389
02/01/2015 Authors: Nastoupil LJ; Shenoy PJ; Ambinder A; Koff JL; Nooka AK; Waller EK; Langston A; Seward M; Kaufman JL; Bernal-Mizrachi L
A time to kill: targeting apoptosis in cancer.
Int J Mol Sci Volume: 16 Page(s): 2942 - 2955
01/28/2015 Authors: Koff JL; Ramachandiran S; Bernal-Mizrachi L
Next-generation prognostic assessment for diffuse large B-cell lymphoma.
Future Oncol Volume: 11 Page(s): 2443 - 2457
01/01/2015 Authors: Staton AD; Koff JL; Chen Q; Ayer T; Flowers CR
Insurance Status Impacts Survival in Follicular Lymphoma
BLOOD Volume: 124
12/06/2014 Authors: Nastoupil LJ; Han X; Jemal A; Ward E; Flowers CR
Detection of NFKB2 3'end Loos By Quantitative PCR (QPCR) or Detection of NFKB2 Rearrangements Correlate with Bortezomib Response in Multiple Myeloma
Volume: 124
12/06/2014 Authors: Ramachandiran S; Koff JL; Garderet L; Saxe D; Ikhlef S; Kelkar N; Kaplan L; El-Cheikh J; Switchenko JM; Sunay S
Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms.
Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): 460 - 467.e2
12/01/2014 Authors: Read JA; Koff JL; Nastoupil LJ; Williams JN; Cohen JB; Flowers CR
Puffing the 'Activate' in Activated B Cell-like Diffuse Large B Cell Lymphoma: A Role for the Noncanonical NF-kappa B Pathway
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 14 Page(s): S143 - S143
09/01/2014 Authors: Koff JL; Guo X; Ramachandiran S; Switchenko JM; Mosunjac MB; Neill SG; Mann K; Bagirov M; Flowers CR; Lossos IS
Relationship Between Residential Proximity To Environmental Protection Agency (EPA) Designated Toxic Release Sites and The Risk Of Diffuse Large B-Cell Lymphoma (DLBCL)
Volume: 122
11/15/2013 Authors: Bulka C; Nastoupil LJ; Koff J; Bernal L; Ward K; Bayakly R; Switchenko J; Waller L; Flowers CR
Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
Oncology (Williston Park) Volume: 27 Suppl 2 Page(s): 8 - 12
10/01/2013 Authors: Nastoupil LJ; Koff JL; Flowers CR